Skip to content

Clinical study on the treatment of spleen-kidney yang deficiency type ovarian hyperstimulation syndrome by Renwu moxibustion combined with hydroxyethyl starch

Clinical study on the treatment of spleen-kidney yang deficiency type ovarian hyperstimulation syndrome by Renwu moxibustion combined with hydroxyethyl starch

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001418
Enrollment
Unknown
Registered
2025-07-16
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrome

Interventions

comparison group:Hydroxyethyl starch sodium chloride injection treatment
Observation Group:Renwu moxibustion combined with hydroxyethyl starch therapy

Sponsors

Shenzhen Maternity and Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Those who meet the diagnostic criteria of spleen and kidney yang deficiency in ovarian hyperstimulation syndrome; 2) Patients aged 20-40 years old; 3) Those who are assisted in conception by assisted reproductive technology for the first time; 4) Those who have not participated in other clinical studies for at least 15 days prior to treatment; 5) Those who have signed the informed consent form and voluntarily participate in this study; 6) Those who have not used other drugs for at least 15 days prior to treatment; 7)Those who are not associated with skin allergy.

Exclusion criteria

Exclusion criteria: 1) Those who do not meet the diagnostic criteria and inclusion criteria; 2) Those with other gynecological diseases in combination such as uterine fibroids uterine malformations endometriosis and cervical insufficiency and other reproductive tract abnormalities; 3)Patients with severe liver and kidney diseases and primary cardiovascular diseases; 4)Patients with poor compliance or mental illness; 5) Those with skin allergy; 6) Patients who have withdrawn from the clinical study automatically.

Design outcomes

Primary

MeasureTime frame
nterleukin 6;effective rate;

Secondary

MeasureTime frame
ovarian diameter;erythrocyte product;abdominal circumference;progesterone;albumin;Chinese Medicine Symptoms Efficacy Score;pelvic fluid;vascular endothelial growth factor;Body mass;fibrinogen;estradiol;

Countries

China

Contacts

Public ContactJiaMan Wu

Shenzhen Maternal and Child Health Center

wujiaman202@163.com+86 158 1747 0407

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026